| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8441618 | European Journal of Cancer | 2016 | 9 Pages |
Abstract
The incidence of cardiotoxicity among women treated with trastuzumab for HER2-positive MBC appeared higher than that reported in RCTs, particularly in elder patients. In spite of this, median survival, was, if anything, better.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Marta Rossi, Greta Carioli, Martina Bonifazi, Alberto Zambelli, Matteo Franchi, Lorenzo Moja, Antonella Zambon, Giovanni Corrao, Carlo La Vecchia, Carlo Zocchetti, Eva Negri,